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MaBACKGROUND Important improvements have been made in treatment of diseases associated with atrial ﬁbrillation
(AF), such as hypertension, myocardial infarction, and heart failure. Incidence rates and risk factors may have changed
with the aging of the population and changing lifestyles. Currently, the risk for AF is only partially explained, possibly
because of differences between older cohorts and contemporary populations.
OBJECTIVES This study investigated the incidence of AF in a contemporary cohort in the Netherlands, together with
comorbidities associated with AF and associations of AF with cardiovascular outcomes.
METHODS Incident AF was ascertained for hospital and study electrocardiograms in 8,265 participants of the PREVEND
(Prevention of Renal and Vascular End-Stage Disease) study in Groningen, the Netherlands.
RESULTS During 9.7  2.3 years of follow-up, 265 participants developed AF, with a resulting overall AF incidence of
3.3 per 1,000 person-years. Advancing age, male sex, antihypertensive drug use, higher body mass index, previous
myocardial infarction, and previous stroke were associated with AF. After multivariable adjustment, AF was associated
with cardiovascular events (hazard ratio [HR]: 2.24; 95% conﬁdence interval [CI]: 1.06 to 4.75; p ¼ 0.035), heart failure
with either reduced or preserved ejection fraction (HR: 4.52; 95% CI: 2.02 to 10.09; p < 0.001), and all-cause mortality
(HR: 3.02; 95% CI: 1.73 to 5.27; p < 0.001).
CONCLUSIONS The incidence of AF in the present cohort was comparable to that shown in data of older studies. Obesity
has become a major risk factor for incident AF. Although overall cardiovascular event rates were lower in the present
study, the present study conﬁrms the association of incident AF with such events. (J Am Coll Cardiol 2015;66:1000–7)
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
BMI = body mass index
ECG = electrocardiogram
ICD = International
Classiﬁcation of Diseases
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal
prohormone of brain
uretic peptide
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1001incidence, prevalence, risk factors, and associated
cardiovascular morbidity and mortality is derived
from predominantly North American cohort studies
that were initiated a long time ago or, more recently,
from registries based on questionnaires or Interna-
tional Classiﬁcation of Diseases (ICD) discharge codes
(5–10). In recent years, important improvements were
made in pharmacological and nonpharmacological
treatment of associated diseases, such as hyperten-
sion, myocardial infarction, and heart failure (11–13).
In addition, incidence rates and risk factors may have
changed with the aging of the population and
changing lifestyles. Currently, the risk for incident AF
is only partially explained, possibly because of dif-
ferences between older cohorts and more contempo-
rary populations. We investigated the incidence of
AF, comorbidities associated with AF, and the asso-
ciations of AF with cardiovascular events, systolic
and diastolic heart failure, and all-cause mortality in
the Dutch community-based PREVEND (Prevention of
Renal and Vascular End-Stage Disease) cohort study.FIGURE 1 AF Ascertainment in the PREVEND Study
PREVEND participants (n = 8,592)
No ECG data available
(n = 248)
PREVEND participants (n = 8,344)
ECGs from PREVEND visits, UMCG and Martini Hospital
Electronic ECG screening (number of ECGs  =  40,890)
Expert panel review
AF suspected
(n = 1,844)
Definite diagnosis of incident AF (n = 265)
•60 at PREVEND follow-up visit
•205 during hospital visits
No AF detected
(n = 6,500)
No AF diagnosed
(n = 1,500)
Mean follow-up 9.7 ± 2.3 years
Flowchart of atrial ﬁbrillation (AF) assessment in PREVEND (Prevention of Renal and
Vascular End-Stage Disease) study participants, by using electrocardiograms (ECGs) made
during PREVEND study visits and hospital visits. UMCG ¼ University Medical Center
Groningen.
SEE PAGE 1008METHODS
POPULATION. The PREVEND cohort study was
founded in 1997 by inviting all inhabitants of the city
of Groningen, the Netherlands, who were 28 to
75 years old (n ¼ 85,421) (14). Of all invitees, 40,856
responded (47.8%). Persons with urinary albumin
excretion >10 mg/l (n ¼ 7,768) in their morning urine,
as well as a randomly selected control group with
urinary albumin excretion <10 mg/l (n ¼ 3,394), were
invited to the PREVEND outpatient clinic. After
excluding patients with insulin-dependent diabetes
mellitus, pregnant women, and persons unable or
unwilling to participate, a ﬁnal cohort of 8,592
patients was included and completed the baseline
screening program. The baseline screening program
consisted of 2 outpatient visits to assess demographic
factors, anthropometric measurements, cardiovascu-
lar and metabolic risk factors, and health behavior
and to collect blood samples and 2 24-h urine
samples on 2 consecutive days. Participants were
seen at 3-year intervals in the PREVEND outpatient
clinic. For the present analysis, we excluded partici-
pants without an electrocardiogram (ECG) (n ¼ 248),
as well as participants with prevalent AF at the
baseline screening (n ¼ 79), thus leaving 8,265 par-
ticipants. The PREVEND study was approved by
the institutional medical ethics committee and con-
ducted in accordance with the Declaration of Helsinki.
All participants provided written informed consent.ASSESSMENT OF AF. Incident AF was diag-
nosed if either atrial ﬂutter or AF was present
on a 12-lead ECG obtained at 1 of the 3 PRE-
VEND follow-up visits or at an outpatient
visit or hospital admission in the 2 hospitals
in the city of Groningen (University Medical
Center Groningen and Martini Hospital). A
standard 12-lead ECG was performed at each
PREVEND follow-up visit. All ECGs were
digitally stored and electronically screened
for the following criteria: PR interval absence,
atrial ﬂutter, or ectopic atrial rhythm. This
method of electronic screening was validated with
complete manual screening by 2 independent ob-
servers of all ECGs from the PREVEND baseline visit,
and 100% sensitivity for the detection of AF or atrial
ﬂutter was reached. All ECGs determined by elec-
tronic screening to suggest suspected AF were
manually reviewed by 2 independent observers.
When an inconsistency was found or when both ob-
servers agreed on the diagnosis of AF or atrial ﬂutter,
the ECGs were validated by 2 independent cardiolo-
gists (Figure 1). Incident AF was diagnosed in 265
participants. For the date of incident AF, the date of
the ﬁrst ECG with a deﬁnite diagnosis of AF or atrial
ﬂutter was used.
COVARIATE DEFINITIONS. Systolic and diastolic
blood pressures were calculated as the mean of the
last 2 measurements of the 2 visits, by using an
natri
TABLE 1 Participants’ Characteristics
Incident AF
(n ¼ 265)
No AF
(n ¼ 8,000) p Value
Age, yrs 62  9 49  13 <0.001
Male 185 (70) 3,935 (49) <0.001
Caucasian 252 (95) 7,592 (95) 1.000
BMI, kg/m2 28  4 26  4 <0.001
Obesity 61 (23) 1,226 (15) 0.001
Systolic blood pressure, mm Hg 143  23 129  20 <0.001
Diastolic blood pressure, mm Hg 78  10 74  10 <0.001
Heart rate, bpm 67  11 69  10 0.002
Antihypertensive drug use 99 (37) 999 (12) <0.001
Hypertension 145 (54) 2,092 (26) <0.001
Previous myocardial infarction 41 (15) 210 (3) <0.001
Heart failure 6 (2.3) 12 (0.2) <0.001
Diabetes mellitus 23 (9) 287 (4) <0.001
Previous stroke 7 (2.6) 50 (0.6) 0.002
Peripheral artery disease 28 (11) 263 (3) <0.001
Smoking 97 (37) 3,573 (45) 0.012
Alcohol consumption 31 (12) 1,023 (13) 0.641
Hypercholesterolemia 35 (13) 326 (4) <0.001
PR interval duration, ms 168 (153–187) 158 (143–172) <0.001
eGFR, ml/min 75 (68–84) 80 (72–90) <0.001
UAE, mg/24 h 16 (8–39) 9 (6–17) <0.001
NT-proBNP, ng/l 103 (44–248) 36 (16–70) <0.001
Highly sensitive CRP, mg/l 2.0 (0.8–3.6) 1.3 (0.6–2.9) <0.001
Values are mean  SD, n (%), or median (interquartile range).
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CRP ¼ C-reactive protein; eGFR ¼ estimated
glomerular ﬁltration rate; NT-proBNP ¼ N-terminal prohormone of brain natriuretic peptide;
UAE ¼ 24-h urine albumin excretion.
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1002automatic Dinamap XL Model 9300 series device
(Johnson & Johnson Medical Inc., Tampa, Florida).
Hypertension was deﬁned as systolic blood pressure
>140 mm Hg, diastolic blood pressure >90 mm Hg, or
use of antihypertensive drugs. Body mass index (BMI)
was calculated as the ratio of weight to height
squared (kg/m2), and obesity was deﬁned as a BMI
>30 kg/m2. Type 2 diabetes was deﬁned as a fasting
plasma glucose >7.0 mmol/l (126 mg/dl), a nonfasting
plasma glucose >11.1 mmol/l, or use of antidiabetic
drugs. Urinary albumin excretion was calculated as
the average value from 2 consecutive 24-h urine col-
lections. The estimated glomerular ﬁltration rate
was estimated using the simpliﬁed modiﬁcation of
diet in renal disease formula. Smoking was deﬁned as
current nicotine use or having stopped smoking
within the previous 5 years. Hypercholesterolemia
was deﬁned as total serum cholesterol >6.5 mmol/l
(251 mg/dl), serum total cholesterol $5.0 mmol/l
(193/mg/dl) if a history of myocardial infarction was
present, or use of lipid-lowering drugs. Alcohol con-
sumption was deﬁned as 4 alcoholic drinks/day or
more in men and 1 to 3 alcoholic drinks/day or more in
women. History of myocardial infarction or strokewas deﬁned as participant-reported hospitalization
for at least 3 days as a result of this condition.
Peripheral artery disease was deﬁned as an ankle-
brachial index <0.9. A committee of experts in heart
failure adjudicated all participants with heart failure
at baseline according to previously published criteria
(14). N-terminal prohormone of brain natriuretic
peptide (NT-proBNP) and highly sensitive C-reactive
protein were measured as described previously
(15,16).
FOLLOW-UP. The follow-up duration was calculated
as the time between the baseline screening visit and
the last contact date, death, or December 31, 2008
(end of the third PREVEND follow-up visit), which-
ever came ﬁrst.
CARDIOVASCULAR EVENTS, HEART FAILURE, AND
ALL-CAUSE MORTALITY ASSESSMENT. Information on
cardiovascular events was obtained from PRISMANT,
the Dutch national registry of hospital discharge
diagnoses. The validity of this database has been
conﬁrmed before, with 84% of primary diagnoses and
87% of secondary diagnoses matching the diagnoses
recorded in participants’ charts (17). Use of hospital
discharge diagnoses and government vital statistics
was part of the original study design (18). Data were
coded according to the 10th revision of the ICD.
Cardiovascular events consisted of cardiac events
(acute myocardial infarction [ICD code 410], acute
and subacute ischemic heart disease [ICD 411],
coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty), cerebrovascular
events (occlusion or stenosis of the precerebral
[ICD 433] or cerebral arteries [ICD 434], subarachnoid
hemorrhage [ICD 430]), and peripheral events (other
vascular interventions such as percutaneous trans-
luminal angioplasty or bypass grafting of the aorta and
peripheral vessels). A committee of experts on heart
failure adjudicated all incident heart failure events
according to previously published criteria and cate-
gorized these events, on the basis of the left ventricular
ejection fraction (LVEF) and diastolic dysfunction,
into either heart failure with reduced ejection fraction
(LVEF <40%) or heart failure with preserved ejection
fraction (LVEF >50%) (14). Six participants with heart
failure had an LVEF of 41% to 49%. These patientswere
included in the total number of patients with heart
failure but were not involved in analyses speciﬁc for
this group because of the low number of events. There
was no classiﬁcation made on the basis of underlying
cause because many patients with heart failure have
more than one comorbidity. Data on mortality were
obtained through the municipal registration. Cause of
death was ascertained by linking the number of the
FIGURE 2 AF Incidence in the PREVEND Study
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(A) Incidence rate of atrial ﬁbrillation (AF) as a function of age for men and women. The
95% conﬁdence intervals are shown using error bars. (B) Cumulative incidence rate of AF
as a function of age for men and women. The salmon line is the (smoothed) cumulative
incidence rate curve for men; the blue line is the cumulative incidence rate curve for
women. The 95% conﬁdence intervals are shown using shaded areas. The cumulative
incidence rate at a given age is the incidence rate of atrial ﬁbrillation in the group of
all people younger than the given age. Incidence rates are per 1,000 person-years of
follow-up. PREVEND ¼ Prevention of Renal and Vascular End-Stage Disease.
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1003death certiﬁcate to the primary cause of death as coded
by the Dutch Central Bureau of Statistics. Information
on dates and causes of death for every participant was
obtained from Statistics Netherlands (19), according to
the 10th revision of the ICD.
STATISTICAL ANALYSIS. We used a statistical
weighting method to adjust for the oversampling of
patients with microalbuminuria at the study’s start
and to allow generalization of results to the general
population (16). Participants’ characteristics were
presented as mean  SD or median (range) for con-
tinuous variables and counts with percentages for
categorical variables. Incidence rates for the number
of AF cases or outcome events per 1,000 person-
years of observation and 95% conﬁdence intervals
(95% CIs) were calculated (20). We estimated multi-
variable Cox proportional hazards regression models
to assess risk factors for incident AF during follow-
up; death was considered a censoring event. We
examined the proportionality assumption by calcu-
lating the Schoenfeld residuals and by plotting the
scaled Schoenfeld residuals against time. There were
no violations of the proportional hazards assump-
tion. We selected risk factors for the incident AF
analyses on the basis of earlier reports and avail-
ability in clinical practice (11,12). Age- and sex-
adjusted covariates with a p <0.1 were stepwise
incorporated in a multivariable-adjusted model, with
the order based on the highest Wald statistic. The
ﬁnal multivariable model included all covariates
with p <0.05. Finally, interactions in the multivariate
model were tested. In view of multiple testing,
we applied a Bonferroni correction to the interac-
tion analysis, to minimize false-positive ﬁndings.
Population-attributable risks for reversible or treat-
able risk factors in the multivariate model were
calculated using the following formula: ([total AF
incidence rate  unexposed AF incidence rate] /
[total AF incidence rate])  100% (21). We used Cox
time-dependent regression analyses, with AF as
time-varying covariate to study the association of
incident AF and future cardiovascular events, heart
failure, and all-cause mortality. We adjusted for
clinically signiﬁcant covariates, on the basis of earlier
publications (22–24). In Model 1 we adjusted for age
and sex, and in Model 2 we adjusted for age, sex,
heart failure, antihypertensive drug use, diabetes,
previous stroke, previous myocardial infarction, pe-
ripheral artery disease, and NT-proBNP. All analyses
were performed using R package (version 3.0.3; R
Foundation for Statistical Computing, Vienna,
Austria), and a 2-tailed p value <0.05 was considered
statistically signiﬁcant.RESULTS
PARTICIPANTS’ CHARACTERISTICS. The mean age
of PREVEND participants was 49  13 years, and
49.8% were men. Total follow-up duration of 8,265
PREVEND participants was 80,352 person-years.
During a mean follow-up of 9.7  2.3 years, 265
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1004(80 women, 185 men) participants (3%) developed AF
(AF incidence rate: 3.3 per 1,000 person-years; 95%
CI: 3.0 to 3.8) (Table 1). Participants with incident AF
were 62  9 years of age, and 70% were men. Of the
265 participants with incident AF, 60 (23%) received
the diagnosis at a PREVEND visit, and the other 205
(77%) received the diagnosis at a hospital visit or
admission. Both cumulative and noncumulative
incidence rates for incident AF stratiﬁed by age and
sex demonstrated higher AF incidence rates in older
persons (Figures 2A and 2B). The primary comorbid-
ities in participants with incident AF were hyperten-
sion (54%), obesity (23%), and previous myocardial
infarction (15%).
RISK FACTORS OF INCIDENT AF. Age- and sex-
adjusted analyses revealed that higher BMI, higher
systolic blood pressure, antihypertensive drug use,
previous myocardial infarction, heart failure, previ-
ous stroke, lower heart rate, and higher NT-proBNP
were associated with an increased risk of incident
AF (Table 2). After stepwise addition of covariates, the
ﬁnal multivariable model consisted of 6 covariates
(Central Illustration): advancing age, male sex, BMI,
antihypertensive drug use, previous myocardial
infarction, and previous stroke. There were no sig-
niﬁcant interactions in the multivariate model.
Population-attributable risk estimates for the most
signiﬁcant reversible or treatable risk factors for
incident AF were calculated: the risk factor that
contributed most to incident AF in the present
population was antihypertensive drug use (32%),
followed by previous myocardial infarction (16%),
obesity (9%), and previous stroke (3%).
ASSOCIATIONS OF AF WITH CARDIOVASCULAR EVENTS,
HEART FAILURE, AND ALL-CAUSE MORTALITY.
Incidence rates of cardiovascular outcomes for par-
ticipants with and without incident AF are described
in Table 3. The incidence of cardiovascular events inTABLE 2 Age- and Sex-Adjusted Cox Proportional Hazards
Models for Determinants of Incident AF
Covariate
Hazard Ratio
(95% CI) p Value
BMI, per 5 kg/m2 1.45 (1.21–1.74) <0.001
Systolic blood pressure, per 10 mm Hg 1.11 (1.01–1.22) 0.025
Heart rate, per 5 bpm 0.89 (0.81–0.98) 0.022
Antihypertensive drug use 2.14 (1.43–3.20) <0.001
Previous myocardial infarction 2.56 (1.51–4.35) <0.001
Heart failure 2.72 (1.06–6.97) 0.037
Previous stroke 4.63 (1.50–14.26) 0.008
NT-proBNP (per 1,000 ng/l) 1.08 (1.07–1.10) <0.001
CI ¼ conﬁdence interval; other abbreviations as in Table 1.participants with AF was higher compared with par-
ticipants without AF (incidence rate per 1,000 person-
years: 20.59; 95% CI: 14.84 to 28.64 vs. 10.13; 95% CI:
9.43 to 10.87, respectively; hazard ratio [HR]: 1.97;
95% CI: 1.24 to 3.13). Cardiac events were most com-
mon, followed by cerebrovascular and peripheral
events. The incidence rate per 1,000 person-years of
heart failure after diagnosis of AF was 18.14 (95% CI:
13.19 to 25.01), compared with 2.91 (95% CI: 2.55 to
3.31) in participants without AF (HR: 6.01; 95% CI:
2.83 to 12.76). Heart failure with reduced ejection
fraction was more common than heart failure with
preserved ejection fraction. The incidence rate per
1,000 person-years of all-cause mortality after diag-
nosis of AF was 28.96 (95% CI: 23.05 to 36.42),
compared with 6.84 (95% CI: 6.28 to 7.44) in partici-
pants without AF (HR: 4.14; 95% CI: 2.64 to 6.51).
Incident AF was associated with cardiovascular
events (multivariable adjusted HR: 2.24; 95% CI: 1.06
to 4.75; p ¼ 0.035), with heart failure (multivariable
adjusted HR: 4.52; 95% CI: 2.02 to 10.09; p < 0.001),
and with all-cause mortality (multivariable adjusted
HR: 3.02; 95% CI: 1.73 to 5.27; p < 0.001) (Table 4).
Incident AF was associated with both heart failure
with reduced ejection fraction (multivariable adjusted
HR: 4.00; 95% CI: 1.49 to 10.73; p ¼ 0.006) and heart
failure with preserved ejection fraction (multivariable
adjusted HR 6.82; 95% CI: 2.47 to 18.79; p < 0.001).
DISCUSSION
The present contemporary community-based study in
the Netherlands had 3 primary ﬁndings. First, the AF
incidence in the present population was 3.3 per 1,000
person-years, comparable to that in older epidemio-
logical studies. Second, in addition to the conven-
tional risk factors for AF, BMI was strongly associated
with AF. Third, we conﬁrmed that AF, despite lower
overall event rates, is associated with an adverse
outcome.
INCIDENCE OF AF. In the present study, we identi-
ﬁed 265 participants with incident AF, and the overall
incidence rate of AF was 3.3 per 1,000 person-years.
AF incidence was higher in men than in women, and
there was a strong increase with age that is compa-
rable to other studies (5–8,25). The incidence is lower
than observed in the Rotterdam Study, also from the
Netherlands, in which the overall incidence rate of AF
was 9.9 per 1,000 person-years. This variation is
probably caused by the age difference of included
participants (in Rotterdam, >55 years; in PREVEND,
between 28 and 75 years) (25). Many of the epi-
demiological studies on AF—the Olmsted County
study (AF documented from 1980 to 2000) (8), the
CENTRAL ILLUSTRATION AF in a Community-Based Cohort in the Netherlands: Multivariate Determinants of
Incident AF
Vermond, R.A. et al. J Am Coll Cardiol. 2015; 66(9):1000–7.
p <0.001 p <0.001
p <0.001 p =0.044
p =0.042
p =0.017
Bars represent the hazard ratio for incident atrial ﬁbrillation (AF) of each individual risk factor in the multivariate model. The 95% conﬁdence
intervals (CIs) are shown under each bar. BMI ¼ body mass index; HT ¼ antihypertensive; MI ¼ myocardial infarction.
TABLE 3 Incidence Rates of Cardiovascular Events, Heart Failure, and
All-Cause Mortality per 1,000 Person-Years
Incidence Rate per 1,000 Person-Years
(95% CI)
Hazard Ratio
(95% CI)
Incident AF
(n ¼ 265)
No AF
(n ¼ 8,000)
Cardiovascular events* 20.59 (14.84–28.64) 10.13 (9.43–10.87) 1.97 (1.24–3.13)
Cerebrovascular events 5.53 (3.26–9.46) 2.42 (2.10–2.79) 2.23 (0.99–5.00)
Cardiac events 14.58 (10.05–21.21) 7.54 (6.95–8.19) 1.88 (1.12–3.16)
Peripheral events 1.63 (0.66–4.17) 0.72 (0.56–0.94) 2.20 (0.52–9.37)
Heart failure 18.14 (13.19–25.01) 2.91 (2.55–3.31) 6.01 (2.83–12.76)
LVEF <40% 12.75 (8.72–18.68) 1.99 (1.70–2.33) 5.79 (2.40–13.98)
LVEF >50%† 4.90 (2.69–9.02) 0.85 (0.67–1.08) 4.80 (1.30–17.70)
All-cause mortality 28.96 (23.05–36.42) 6.84 (6.28–7.44) 4.14 (2.64–6.51)
*Composite of cardiovascular events; some participants had multiple events. †Six participants with heart failure
had an LVEF of 41% to 49%. To ensure a clear distinction between both systolic and diastolic heart failure, these
participants are not shown in the table.
LVEF ¼ left ventricular ejection fraction; other abbreviations as in Tables 1 and 2.
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1005Cardiovascular Health Study (inclusion from 1989 to
1993; last evaluation for AF in 1996) (6), the Athero-
sclerosis Risk in Communities study (inclusion from
1987 to 1989; follow-up until 1998) (7), and the Rot-
terdam Study (inclusion from 1990 to 1993; follow-up
until 1999) (25)—followed their participants up to the
21st century, except the Framingham Heart Study
(inclusion from 1948 to 1971; follow-up until 2008)
(4,5), and the Women’s Health Initiative (inclusion
from 1994 to 1998; follow-up until 2007) (21). Our AF
incidence rate is comparable to the incidence rates
described in those older, and predominantly
U.S.-based cohort studies (range, 3.3 to 19.2 per 1,000
person-years) (5–8,25). This is an interesting ﬁnding
because improvements are continuously made in the
treatment of cardiovascular risk factors for AF,
including hypertension, coronary heart disease, and
heart failure (11–13). Whereas improved treatment of
cardiovascular diseases may reduce the risk of
development of AF, increased life expectancy and
changes in lifestyle such as inactivity and obesity may
increase the incidence of AF. Together, these factors
may have resulted in an AF incidence in the present
study that is comparable to that of older studies.
COMORBIDITIES ASSOCIATED WITH INCIDENT AF.
Most data on comorbidities associated with AF in
the general population have been obtained from old
U.S. cohorts that started inclusion before the intro-
duction of contemporary treatments for myocardial
infarction, hypertension and heart failure, andincreasing availability of diagnostic tests, and chang-
ing lifestyle (11–13,26).
Associations of advancing age, male sex, hyper-
tension, coronary heart disease, valve disease, heart
failure, and diabetes mellitus with incident AF have
been well established (4,6,7,21,25). In the present
contemporary Dutch cohort, we found similar asso-
ciations of well-established risk factors. In addition,
obesity was an important contributor to AF risk.
In a report from the third Atrial Fibrillation Compe-
tence NETwork/European Heart Rhythm Association
TABLE 4 Association of Incident AF* With Outcomes
Hazard Ratio (95% CI) p Value
Cardiovascular events
Model 1 2.45 (1.34–4.49) 0.004
Model 2 2.24 (1.06–4.75) 0.035
Heart failure
Model 1 6.11 (3.32–11.23) <0.001
Model 2 4.52 (2.02–10.09) <0.001
All-cause mortality
Model 1 3.79 (2.34–6.14) <0.001
Model 2 3.02 (1.73–5.27) <0.001
*Time-varying covariate. Model 1: adjusted for age and sex. Model 2: adjusted for
age, sex, prevalent heart failure, antihypertensive drug use, diabetes, previous
stroke, previous myocardial infarction, peripheral artery disease, and N-terminal
prohormone of brain natriuretic peptide.
Abbreviations as in Table 1 and 2.
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1006consensus conference published in 2011 (12), BMI was
considered a less-validated risk factor for AF. How-
ever, with a 45% increased risk of AF with every
5 points of BMI increase, the present study supports
the notion that BMI should be regarded as a validated
risk factor for AF.
Obesity often coexists with other cardiovascular
risk factors and diseases (e.g., diabetes, metabolic
syndrome, and sleep apnea syndrome). However,
obesity by itself may also induce AF (21,27). Animal
models of obesity showed the induction of cardiac
ectopic fat and fat inﬁltration of the local atrial
myocardium, potentially a novel substrate speciﬁc to
obesity (28). Importantly, obesity is a modiﬁable risk
factor, and it was shown that strict weight reduction
reduced the AF burden (29). The population-
attributable risk of obesity in this study provides an
indication that a 9% reduction of incident AF could be
achieved when the risk factor obesity was completely
eliminated.
AF-RELATED CARDIOVASCULAR EVENTS, HEART
FAILURE, AND MORTALITY. The present analysis
conﬁrms the association of AF with adverse out-
comes, including cardiovascular events, heart failure,
and all-cause mortality. Treatment of AF has sig-
niﬁcantly changed in the past decade. The most
important change has been systematic use of oral
anticoagulation in persons at risk for stroke (11).
Although the overall event rates were lower in the
present contemporary cohort, the associations with
outcome were similar as previously described. The
lower rates of cardiovascular events, heart failure,
and all-cause mortality may be caused by improved
treatment modalities. However, incident AF was still
associated with a 2-fold increase of cardiovascular
events including stroke, a 5-fold increased heartfailure risk, and a 2-fold increased risk of all-cause
mortality, largely similar to associations found pre-
viously (23,24). Despite the important improvements
in oral anticoagulation reducing the risk of stroke
(30–32), the risk of heart failure and the risk of all-
cause mortality associated with AF are still high
(24). Next to stroke prevention, more focus on pre-
vention of heart failure and mortality in patients with
AF seems important in the years to come, to improve
prognosis of patients with AF further.
STUDY STRENGTHS AND LIMITATIONS. Strengths of
our study are the contemporary cohort, the detailed
clinical assessment, the long and contemporary
follow-up period, and the robust validation of car-
diovascular events, including AF. However, there are
limitations, mainly resulting from the observational
design of this community-based cohort study. We
may have overlooked asymptomatic paroxysmal AF
because we had no continuous ECG recordings (33).
Moreover, given that a cardiovascular event was
attributed to AF only when AF was diagnosed before
the event occurred, the present event rates may be
underestimated. Stroke was deﬁned using ICD codes
for occlusion or stenosis of the precerebral or cerebral
arteries; no direct evaluation for stroke was per-
formed. Data on obstructive sleep apnea were not
available. Although treating physicians were informed
about the presence of AF or other undiagnosed car-
diovascular diseases, treatment was left to the discre-
tion of the physician.
CONCLUSIONS
Results of our contemporary community-based study
from the Netherlands conﬁrm that although impor-
tant progress in treatment of cardiovascular disease is
continuously being made, the incidence of AF has not
dramatically changed over the years. Obesity has
become a major risk factor for incident AF. Whereas
overall cardiovascular event rates were lower in the
present study, incident AF still doubles the cardio-
vascular event risk and the all-cause mortality risk
and increases the heart failure risk 5-fold. Identiﬁca-
tion and improved treatment of reversible risk factors
for incident AF, and prevention of heart failure and
mortality, may prevent AF and improve the prognosis
of this arrhythmia.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Despite
considerable progress in management of cardiovascular
disease, the incidence of AF has not decreased, and this
common rhythm disturbance is associated with adverse
cardiovascular outcomes, including heart failure and
stroke. In addition to well-established factors, obesity has
become a risk factor for AF.
TRANSLATIONAL OUTLOOK: More research should
be directed toward understanding the roles of weight
reduction and lifestyle modiﬁcation in prevention of AF.
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